Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Court Of Appeal To Re-Evaluate NICE Osteoporosis Decision, UK
Servier Laboratories Limited has been granted permission by the Court of Appeal to challenge a High Court decision made at a Judicial Review in February this year, in which Servier was previously successful in its claim that the National Institute for Health and Clinical Excellence (NICE) had unlawfully failed to provide the economic model underlying its Guidance for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. 1,2
generic viagra online
Jet Lag -Trends And Coping Strategies
Frequent air travelers, as well as people who fly only occasionally, are often inconvenienced by the effects of jet lag, according to research presented today at the American College of Sports Medicine"s 56th Annual Meeting in Seattle. Christopher Berger, Ph.D., Chair of the American College of Sports Medicine (ACSM) Task Force on Healthy Air Travel, "Exercise is Medicine™ On the Fly," explains that jet lag, medically called desynchronosis, is the physiological response to alterations to circadian rhythms.
News of the day
Diagnostics Waiting Times & Activity Data: Month Ending March 2009
This data shows the NHS" progress in tackling the waiting times for
Medical Devices

UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323 - Analysis Showed No Clinically Relevant Benefit For Patients

UCB and Biogen Idec announced today the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that patients enrolled in this clinical trial did not benefit as expected from CDP323 compared to placebo after a six month treatment period. No cases of PML (progressive multifocal leukoencephalopathy) were noted. CDP323 is an oral small molecule alpha4 integrin inhibitor that was being developed by UCB and Biogen Idec for relapsing forms of multiple sclerosis. For UCB, results of this interim analysis trigger a re-valuation of the intangible asset "CDP323". UCB expects a non-cash, non-recurring impairment of a high double-digit million pre-tax euro amount. This will be more than compensated by cash, non-recurring capital gains, which resulted from the divestitures UCB made earlier this year. More information on the financial impacts of both the impairment and the capital gains will be included in the Half Year Report 2009 of UCB, due July 31, 2009. About Multiple Sclerosis Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects an estimated 1.1 - 2.5 million people worldwide. Although the exact cause is unknown, MS occurs as a result of loss of the protective outer coating on nerves in the brain and spinal cord. Deterioration in the way that messages are transmitted around the body leads to loss of movement and other body functions. Symptoms of MS can include vision problems, loss of balance, numbness, difficulty walking and paralysis. UCB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009